Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Peritoneal Carcinomatosis: early-phase trial registry
11 of 15 indexed Peritoneal Carcinomatosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 11 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Peritoneal Carcinomatosis: 15 US clinical trials tracked, 11 recruiting.
Peritoneal Carcinomatosis is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is University of California, Irvine, running 3 of these trials.
Enrollment posture brief
Registry condition peritoneal-carcinomatosis
OPEN 11 | RECR 73% | LATE 0 | EARLY 13 | RANK #1140 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Oropharyngeal Squamous Cell Carcinoma (73% recruiting · 15 trials)
Peritoneal Carcinomatosis lists 11 open slots (73% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Peritoneal Carcinomatosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Peritoneal Carcinomatosis is recruiting above its size-band peers.
11 of 15 indexed trials (73.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Peritoneal Carcinomatosis research.
University of California, Irvine accounts for 3 of 15 trials (20%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Peritoneal Carcinomatosis trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 15 trials that report a genuine target (sentinel values excluded). 11 of those (73.3%) plan for fewer than 100 participants.
-
Peritoneal Carcinomatosis research is mostly interventional.
15 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
Patrick Wagner, MD, FACS
NCT07282834
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
ECOG-ACRIN Cancer Research Group
NCT07001748
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Oncoinvent Solutions AS
NCT06504147
Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
Prakash Pandalai
NCT04779554
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
National Cancer Institute (NCI)
NCT04847063
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
Columbia University
NCT03127774
Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)
Rutgers, The State University of New Jersey
NCT04929015
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
University of Chicago
NCT04107077
Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis
University of California, Irvine
NCT05844865
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
NCT06623396
PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis
University of California, Irvine
NCT06511037
Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis
University of California, Irvine
NCT04762953
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
National Cancer Institute (NCI)
NCT05185947
Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI
University of Massachusetts, Worcester
NCT02833753
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
National Cancer Institute (NCI)
NCT04034251
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Peritoneal Carcinomatosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Peritoneal Carcinomatosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Peritoneal Carcinomatosis page
15 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Peritoneal Carcinomatosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of California, Irvine sponsors the most Peritoneal Carcinomatosis trials on record, review their full trial history before evaluating a specific study. See University of California, Irvine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Peritoneal Carcinomatosis condition card totals 15 registered trials; most-linked intervention Paclitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.